Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810625 · ClinicalTrials.gov registry record · Phase 1
Food Effect Study of D-0502 Tablet in Healthy Volunteers
A Phase 1 study, sponsored by InventisBio Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03810625: Completed Phase 1 study, sponsored by InventisBio Co..
NCT03810625 is a Phase 1 study that has completed, run by InventisBio Co.. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810625, a Phase 1 study, has completed, sponsored by InventisBio Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.
Primary Outcome
AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM\*hr
Interventions
- DRUG D-0502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2019-04-17 |
| Phase | Phase 1 |
What the finished NCT03810625 record still lists
NCT03810625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which D-0502 is the first listed.
NCT03810625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03810625 about?
NCT03810625 is a clinical study titled "Food Effect Study of D-0502 Tablet in Healthy Volunteers". This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.
What is the current status of trial NCT03810625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-10-23. Estimated completion is 2019-04-17.
What interventions are being tested in trial NCT03810625?
The interventions under investigation include: D-0502 (DRUG).
Who is sponsoring clinical trial NCT03810625?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03810625's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy